Neuromodulation Shows Some Benefit In Treating Overactive Bladder
This article was originally published in The Gray Sheet
Executive Summary
A procedural therapy may hold more promise for treating overactive bladder than the more conservative medical approach, but it also carries more risks, according to a technology assessment from the Agency for Healthcare Research and Quality
You may also be interested in...
Research In Brief
AHRQ DES study: "Largest ever real-world study" comparing drug-eluting (DES) and bare metal stents (BMS) demonstrates the former were associated with significantly lower rates of death in Medicare patients undergoing percutaneous coronary intervention, Agency for Healthcare Research and Quality concludes in Feb. 10 research report. The study included 217,675 DES patients and 45,025 BMS patients. At 30 months, unadjusted rates of death were 12.9% for DES and 17.9% for BMS. Rates of myocardial infarction and revascularization were, respectively, 7.3 and 23.0 per 100 patients in the DES group, and 10.0 and 24.5 per 100 patients in the BMS arm. DES patients also had lower rates of adjusted death and MI, with minimal difference in revascularization, stroke or bleeding
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.